S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
US Dollar Replaced By "Biden Bucks"? (Ad)
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
One Stock Is All You Need  (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
One Stock Is All You Need  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
US Dollar Replaced By "Biden Bucks"? (Ad)
NASDAQ:EPZM

Epizyme - EPZM Stock Forecast, Price & News

$1.47
-0.02 (-1.34%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.47
$1.50
50-Day Range
$0.52
$1.52
52-Week Range
$0.41
$5.80
Volume
22.12 million shs
Average Volume
3.22 million shs
Market Capitalization
$247.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Epizyme MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
104.1% Upside
$3.00 Price Target
Short Interest
Healthy
1.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
0.96mentions of Epizyme in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

99th out of 1,112 stocks

Pharmaceutical Preparations Industry

37th out of 544 stocks

EPZM stock logo

About Epizyme (NASDAQ:EPZM) Stock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Epizyme Stock Performance

NASDAQ:EPZM traded down $0.01 during midday trading on Thursday, reaching $1.48. The stock had a trading volume of 138,430 shares, compared to its average volume of 2,386,301. Epizyme has a 12-month low of $0.41 and a 12-month high of $5.80. The firm has a fifty day simple moving average of $1.21 and a two-hundred day simple moving average of $1.13.

Epizyme (NASDAQ:EPZM - Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). The firm had revenue of $8.70 million for the quarter, compared to analysts' expectations of $10.86 million. Epizyme had a negative net margin of 391.90% and a negative return on equity of 2,459.33%. During the same period last year, the firm posted ($0.69) EPS. On average, sell-side analysts expect that Epizyme will post -1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Cowen lowered Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target for the company. in a research report on Monday, June 27th. Cowen downgraded Epizyme from an "outperform" rating to a "market perform" rating and set a $1.50 price target on the stock. in a research note on Monday, June 27th. StockNews.com cut Epizyme from a "hold" rating to a "sell" rating in a research note on Monday. HC Wainwright reduced their price target on shares of Epizyme from $8.00 to $6.00 and set a "buy" rating for the company in a research report on Friday, June 3rd. Finally, Wedbush downgraded shares of Epizyme from an "outperform" rating to a "neutral" rating in a research report on Monday, June 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $3.00.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

Epizyme (NASDAQ:EPZM) Stock Rating Lowered by StockNews.com
Epizyme: Q2 Earnings Insights - Benzinga
Epizyme: Q2 Earnings Snapshot
Epizyme (NASDAQ:EPZM) Lifted to Hold at StockNews.com
Epizyme shares soar 60% on acquisition news
See More Headlines
Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Company Calendar

Last Earnings
8/09/2022
Today
8/11/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+104.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-251,120,000.00
Net Margins
-391.90%
Pretax Margin
-613.94%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.54) per share

Miscellaneous

Free Float
128,940,000
Market Cap
$247.44 million
Optionable
Optionable
Beta
-0.41

Key Executives

  • Mr. Grant C. Bogle (Age 64)
    Pres, CEO, Principal Financial Officer & Director
    Comp: $923.32k
  • Dr. Jeffery L. Kutok M.D. (Age 55)
    Ph.D., Chief Scientific Officer
    Comp: $646.13k
  • Dr. H. Robert Horvitz
    Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang
    Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Jerald Korn J.D. (Age 43)
    Chief Operating Officer
  • Mr. Joseph Beaulieu (Age 41)
    Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer
  • Mr. Craig West CFA
    VP of Investor Relations
  • Mr. John F. Weidenbruch (Age 61)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Tanja Weber
    Chief Bus. Officer
  • Dr. Mark A. De Rosch Ph.D. (Age 58)
    Chief Regulatory Officer













EPZM Stock - Frequently Asked Questions

Should I buy or sell Epizyme stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" EPZM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View EPZM analyst ratings
or view top-rated stocks.

What is Epizyme's stock price forecast for 2022?

4 Wall Street research analysts have issued twelve-month target prices for Epizyme's shares. Their EPZM share price forecasts range from $1.50 to $6.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for EPZM
or view top-rated stocks among Wall Street analysts.

How have EPZM shares performed in 2022?

Epizyme's stock was trading at $2.50 on January 1st, 2022. Since then, EPZM stock has decreased by 41.2% and is now trading at $1.47.
View the best growth stocks for 2022 here
.

When is Epizyme's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our EPZM earnings forecast
.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.15. The biopharmaceutical company earned $27.53 million during the quarter, compared to analysts' expectations of $10.11 million. Epizyme had a negative net margin of 391.90% and a negative trailing twelve-month return on equity of 2,459.33%.

What other stocks do shareholders of Epizyme own?

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by many different retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (9.89%), Hennion & Walsh Asset Management Inc. (0.20%), Yakira Capital Management Inc. (0.10%), UBS Group AG (0.04%), FNY Investment Advisers LLC (0.03%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends
.

How do I buy shares of Epizyme?

Shares of EPZM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $1.47.

How much money does Epizyme make?

Epizyme (NASDAQ:EPZM) has a market capitalization of $247.44 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Epizyme have?

The company employs 250 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.

This page (NASDAQ:EPZM) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.